“Milk Sugar 2.0” Cleared for Takeoff: EU Greenlights Next-Gen Human-Identical Oligosaccharide for Infant Nutrition

In a landmark move that could reshape the future of infant formula and functional foods, the European Food Safety Authority (EFSA) has officially declared 6′-sialyllactose (6’-SL) sodium salt—a cutting-edge human milk oligosaccharide (HMO)—safe for consumption under proposed use conditions. Announced on January 30, 2026, this scientific opinion by EFSA’s Panel on Nutrition, Novel Foods and Food Allergens (NDA) paves the way for broader incorporation of this bioactive “milk sugar” into foods designed to mimic the protective power of breast milk.

What makes this approval especially significant is not just what is being approved—but how it’s made. The novel food in question is produced via precision fermentation using a genetically modified strain of Escherichia coli K-12 MG1655 (designated INB-6SL_02). Despite the microbial origin, the resulting compound is chemically identical to 6’-SL found naturally in human breast milk—earning it the label “human-identical milk oligosaccharide” (HiMO). These complex sugars don’t nourish babies directly; instead, they act as prebiotics, feeding beneficial gut bacteria like Bifidobacteria, and may also block pathogen adhesion, support brain development, and modulate immunity.

This isn’t the first time 6’-SL sodium salt has been authorized in the EU. However, the current application represents a refined production process—a new microbial host strain and updated specifications—while keeping target populations, usage levels, and expected intake unchanged. Crucially, EFSA confirmed that the composition remains consistent: primarily 6’-SL sodium salt, with minor amounts of d-lactose, sialic acid, 6′-sialyllactulose, and trace related saccharides—all deemed safe.

The safety assessment leaned heavily on a powerful benchmark: comparing estimated intake from fortified foods to the natural levels consumed by breastfed infants. Since the proposed use mirrors that of already-approved 6’-SL products, and because toxicological data raised no red flags, EFSA concluded there are no safety concerns at the intended doses.

This decision arrives amid surging global demand for advanced infant nutrition. Parents and manufacturers alike seek formulas that go beyond basic macronutrients to replicate the biofunctional complexity of human milk. With over 200 different HMOs identified in breast milk, 6’-SL is among the most abundant—and now, one of the most accessible.

Importantly, EFSA emphasized that other structurally related carbohydrates present in the product also pose no safety risk, reinforcing confidence in the purity and predictability of the fermentation process. The E. coli K-12 strain used is a well-characterized, non-pathogenic laboratory workhorse, extensively used in biotech for decades and incapable of surviving outside controlled environments.

For the food industry, this opinion unlocks new formulation possibilities—not just in infant formula, but potentially in toddler milks, medical foods, and even adult gut-health products. As regulatory pathways for HiMOs mature across Europe, the U.S., and Asia, companies investing in synthetic biology platforms stand to benefit from a convergence of science, safety, and consumer trust.

With EFSA’s stamp of approval, 6’-SL sodium salt moves from lab curiosity to mainstream ingredient—bringing science one step closer to bottling the brilliance of breast milk. In the quest to nourish the next generation, nature’s blueprint is now being faithfully rewritten—one sugar molecule at a time.